2seventy bio (TSVT) to Release Earnings on Wednesday

2seventy bio (NASDAQ:TSVT - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect 2seventy bio to post earnings of ($0.10) per share and revenue of $13.96 million for the quarter.

2seventy bio (NASDAQ:TSVT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.11. 2seventy bio had a negative return on equity of 53.65% and a negative net margin of 207.25%. The company had revenue of $22.94 million for the quarter, compared to the consensus estimate of $13.96 million. On average, analysts expect 2seventy bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

2seventy bio Price Performance

NASDAQ:TSVT traded up $0.01 during mid-day trading on Monday, reaching $5.00. 801,813 shares of the company's stock traded hands, compared to its average volume of 622,914. 2seventy bio has a 12-month low of $2.29 and a 12-month high of $5.30. The firm has a market capitalization of $265.88 million, a price-to-earnings ratio of -2.69 and a beta of 1.04. The company has a 50 day moving average price of $4.79 and a 200-day moving average price of $3.75.

Insider Buying and Selling

In other news, CEO William D. Baird III sold 5,092 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $4.95, for a total transaction of $25,205.40. Following the transaction, the chief executive officer now directly owns 1,121,034 shares of the company's stock, valued at $5,549,118.30. This represents a 0.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total value of $25,350,607.23. The disclosure for this sale can be found here. Insiders have sold 5,152,093 shares of company stock worth $25,400,018 in the last 90 days. Insiders own 7.20% of the company's stock.

Analyst Ratings Changes

TSVT has been the topic of a number of research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of 2seventy bio in a report on Saturday. Leerink Partnrs downgraded 2seventy bio from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 11th. Leerink Partners reiterated a "market perform" rating and set a $5.00 target price (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday, March 11th. Finally, Morgan Stanley reduced their target price on 2seventy bio from $6.00 to $5.00 and set an "equal weight" rating on the stock in a report on Friday, March 14th. One research analyst has rated the stock with a sell rating and four have issued a hold rating to the company's stock. According to MarketBeat.com, 2seventy bio has a consensus rating of "Hold" and an average target price of $4.25.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.